GeneDx Holdings Corp. Insider Trading Activity
Every SEC Form 4 insider transaction reported for GeneDx Holdings Corp. (WGS), sourced directly from SEC EDGAR and updated as new filings are accepted.
By Trabud · Insider-trading data from SEC EDGAR
Latest filing:
Compiled automatically from SEC EDGAR Form 4 filings and refreshed daily. Figures count purchases (code P) and sales (code S) only — not grants, option exercises, or gifts. How this page is built. Not investment advice.
Quick Answer
Are WGS insiders buying or selling?
In the last 12 months, GeneDx Holdings Corp. insiders reported 5 open-market purchases ($106.6M) and 33 sales ($21.8M) — net buying of $84.8M. Since November 2021, Trabud has recorded 232 Form 4 filings for WGS: 26 buys ($305.8M) and 206 sells ($241.3M).
Source: SEC EDGAR Form 4
What stands out
- The largest open-market purchase in the last 12 months was $46.8M by Keith A. Meister (Director, 10% Owner) on May 12, 2026. SEC ↗
- The most recent open-market purchase was reported on Jun 8, 2026 (4 months ago).
Key Statistics (November 2021 – Sep 18, 2026)
Total Form 4 filings
232
SEC EDGAR
Insider filers
22
Insider buys (26)
$305.8M
Insider sells (206)
$241.3M
Insider sentiment
Net buyingNet insider flow of $64.5M in net buying since November 2021, and $84.8M in net buying over the last 12 months.
Recent WGS insider transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Sep 18, 2026 | Katherine Stueland | CHIEF EXECUTIVE OFFICER | Sale | 10.5K | $97.61 | $1.0M | SEC ↗ |
| Sep 18, 2026 | Kevin Feeley | CHIEF FINANCIAL OFFICER | Sale | 3.7K | $97.61 | $363.9K | SEC ↗ |
| Sep 11, 2026 | Katherine Stueland | CHIEF EXECUTIVE OFFICER | Sale | 3.7K | $84.22 | $310.9K | SEC ↗ |
| Sep 11, 2026 | Kevin Feeley | CHIEF FINANCIAL OFFICER | Sale | 1.3K | $84.22 | $108.2K | SEC ↗ |
| Sep 3, 2026 | Kevin Feeley | CHIEF FINANCIAL OFFICER | Sale | 372 | $83.84 | $31.2K | SEC ↗ |
| Jun 18, 2026 | Kevin Feeley | CHIEF FINANCIAL OFFICER | Sale | 3.7K | $60.77 | $226.6K | SEC ↗ |
| Jun 18, 2026 | Katherine Stueland | CHIEF EXECUTIVE OFFICER | Sale | 10.5K | $60.77 | $638.1K | SEC ↗ |
| Jun 11, 2026 | Kevin Feeley | CHIEF FINANCIAL OFFICER | Sale | 1.3K | $53.77 | $68.1K | SEC ↗ |
| Jun 11, 2026 | Katherine Stueland | CHIEF EXECUTIVE OFFICER | Sale | 3.6K | $53.77 | $195.7K | SEC ↗ |
| Jun 8, 2026 | Eli Casdin | Director, 10% Owner | Purchase | 200.0K | $55.55 | $11.1M | SEC ↗ |
| Jun 3, 2026 | Kevin Feeley | CHIEF FINANCIAL OFFICER | Sale | 369 | $51.74 | $19.1K | SEC ↗ |
| May 20, 2026 | Eli Casdin | Director, 10% Owner | Purchase | 500.0K | $42.92 | $21.5M | SEC ↗ |
| May 15, 2026 | Keith A. Meister | Director, 10% Owner | Purchase | 351.3K | $39.19 | $13.8M | SEC ↗ |
| May 12, 2026 | Keith A. Meister | Director, 10% Owner | Purchase | 1.2M | $38.84 | $46.8M | SEC ↗ |
| May 1, 2026 | Katherine Stueland | CHIEF EXECUTIVE OFFICER | Sale | 2.2K | $65.19 | $141.6K | SEC ↗ |
| May 1, 2026 | Kevin Feeley | CHIEF FINANCIAL OFFICER | Sale | 392 | $65.19 | $25.6K | SEC ↗ |
| Mar 30, 2026 | Kevin Feeley | CHIEF FINANCIAL OFFICER | Sale | 8.8K | $63.17 | $557.1K | SEC ↗ |
| Mar 30, 2026 | Katherine Stueland | CHIEF EXECUTIVE OFFICER | Sale | 46.9K | $63.17 | $3.0M | SEC ↗ |
| Mar 17, 2026 | Katherine Stueland | CHIEF EXECUTIVE OFFICER | Sale | 17.2K | $76.80 | $1.3M | SEC ↗ |
| Mar 17, 2026 | Kevin Feeley | CHIEF FINANCIAL OFFICER | Sale | 5.7K | $76.80 | $438.2K | SEC ↗ |
| Mar 11, 2026 | Kevin Feeley | CHIEF FINANCIAL OFFICER | Sale | 1.3K | $86.75 | $111.0K | SEC ↗ |
| Mar 11, 2026 | Katherine Stueland | CHIEF EXECUTIVE OFFICER | Sale | 3.7K | $86.75 | $319.1K | SEC ↗ |
| Mar 6, 2026 | Keith A. Meister | Director, 10% Owner | Purchase | 169.5K | $79.40 | $13.5M | SEC ↗ |
| Mar 5, 2026 | Kevin Feeley | CHIEF FINANCIAL OFFICER | Sale | 6.2K | $78.61 | $486.4K | SEC ↗ |
| Mar 5, 2026 | Katherine Stueland | CHIEF EXECUTIVE OFFICER | Sale | 25.5K | $78.61 | $2.0M | SEC ↗ |
Showing the 25 most recent of 232 Form 4 filings for GeneDx Holdings Corp..
Most active WGS insiders
- Kevin Feeley66 filings
- Katherine Stueland50 filings
- Kareem Saad26 filings
- Karen Ann White15 filings
- OPKO HEALTH, INC.11 filings
Ask anything about WGS insider activity
Use Trabud's AI agent to query GeneDx Holdings Corp.'s Form 4 history in plain English — "Show me WGS CEO purchases this year" or compare it against any other ticker.
Open the AI agentWGS insider trading FAQ
Are GeneDx Holdings Corp. insiders buying or selling?
In the last 12 months, GeneDx Holdings Corp. insiders reported 5 open-market purchases ($106.6M) and 33 sales ($21.8M) — net buying of $84.8M. Since November 2021, Trabud has recorded 232 Form 4 filings for WGS: 26 buys ($305.8M) and 206 sells ($241.3M). Over the full record that is net buying of $64.5M.
How many insiders trade WGS stock?
22 distinct insider filers — officers, directors, 10%+ owners, and investment groups filing jointly — have reported Form 4 transactions for GeneDx Holdings Corp.. The most recent filing was accepted on Sep 18, 2026.
Where does Trabud get WGS insider trading data?
All WGS insider trading data comes directly from official SEC EDGAR Form 4 filings, which corporate insiders must submit within two business days of a transaction under Section 16(a) of the Securities Exchange Act of 1934.